Finepoint Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Finepoint Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-435,785	Closed	-$17M	–	17
2025 Q1	$17M	Sell	435,785 -12,150	-3%	-$524K	1.3%	9
2024 Q4	$24.3M	Buy	447,935 +59,100	+15%	+$3.02M	1.48%	10
2024 Q3	$19.6M	Hold	388,835	–	–	1.42%	10
2024 Q2	$17.1M	Buy	388,835 +27,919	+8%	+$1.18M	4.85%	7
2024 Q1	$18.1M	Sell	360,916 -534,084	-60%	-$29M	4.65%	8
2023 Q4	$62.7K	Buy	895,000 +563,584	+170%	+$29M	0.02%	20
2023 Q3	$18.9M	Buy	331,416 +29,416	+10%	+$1.62M	9.41%	1
2023 Q2	$15.4M	Buy	+302,000	New	+$8.13M	5.33%	10
2021 Q4	–	Sell	-382,400	Closed	-$3.77M	–	73
2021 Q3	$3.77M	Buy	382,400 +32,400	+9%	+$323K	0.64%	42
2021 Q2	$3.62M	Buy	+350,000	New	+$3.55M	0.68%	39

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Finepoint Capital's MLTX Position: Q2 2025 in Review

Finepoint Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 435,785 shares — an estimated $17M sold.

Finepoint Capital first reported a position in MLTX in Q2 2021 and held it in 10 quarters. The position peaked at $24.3M in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

Finepoint Capital reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
Finepoint Capital sold 435,785 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $17M.
Finepoint Capital first reported a position in MoonLake Immunotherapeutics in Q2 2021 and held it in 10 quarters.
Finepoint Capital's MoonLake Immunotherapeutics position peaked at $24.3M in Q4 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on Finepoint Capital's 13F filing for Q2 2025, filed 13 Aug 2025.